<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01743625</url>
  </required_header>
  <id_info>
    <org_study_id>COV15010232</org_study_id>
    <nct_id>NCT01743625</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy Study of COV155 for Post-operative Bunionectomy Pain</brief_title>
  <official_title>A Phase 3 Multicenter, Randomized, Double-blind, Placebo-Controlled, Parallel-Group Evaluation of the Safety and Analgesic Efficacy of COV155 Tablets in Moderate to Severe Post-Operative Bunionectomy Pain Followed by an Open-Label Extension</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mallinckrodt</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mallinckrodt</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to show the effectiveness of COV155 compared to placebo in&#xD;
      subjects with acute moderate to severe pain following bunionectomy surgery.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2012</start_date>
  <completion_date type="Actual">July 2013</completion_date>
  <primary_completion_date type="Actual">May 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>SPID48 (Summed pain intensity difference)</measure>
    <time_frame>48 hours</time_frame>
    <description>48 hour Summed pain intensity difference</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety and tolerability of COV155</measure>
    <time_frame>48 hours</time_frame>
    <description>Safety and tolerability to be evaluated with physical exams, vital signs, pulse oximetry, clinical laboratory tests, electrocardiograms, and adverse events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Onset of analgesia of COV155 versus placebo</measure>
    <time_frame>48 hours</time_frame>
    <description>Onset of confirmed perceptible pain relief, time to meaningful pain relief, and time to peak pain intensity difference</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Analgesic effects of COV155 versus placebo</measure>
    <time_frame>48 hours</time_frame>
    <description>Pain intensity scores, pain intensity differences, and summed pain intensity differences; pain relief scores and total pain relief; percent responders; mean dosing interval; use of rescue medication; global assessment of subject satisfaction with study treatment.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">406</enrollment>
  <condition>Pain, Postoperative</condition>
  <condition>Bunion</condition>
  <arm_group>
    <arm_group_label>COV155</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>COV155, loading dose of 3 tablets followed by 2 tablets every 12 hours for 48 hours.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Matching tablet to COV155 without containing active ingredients, loading dose of 3 tablets followed by 2 tablets every 12 hours for 48 hours.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>COV155</intervention_name>
    <description>COV155 tablets</description>
    <arm_group_label>COV155</arm_group_label>
    <other_name>MNK155</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
          -  Voluntarily provide written informed consent&#xD;
&#xD;
          -  General good health&#xD;
&#xD;
          -  18 to 75 years of age&#xD;
&#xD;
          -  Scheduled for primary unilateral first metatarsal bunionectomy (with no collateral&#xD;
             procedures)&#xD;
&#xD;
          -  Body mass index ≤33&#xD;
&#xD;
          -  Female subjects eligible if&#xD;
&#xD;
               -  Not pregnant or lactating; not planning to become pregnant for duration of study;&#xD;
&#xD;
               -  Surgically sterile, or have a monogamous partner who is surgically sterile, or at&#xD;
                  least 2 years postmenopausal, or practicing acceptable birth control for more&#xD;
                  than 2 months prior to Screening, during the study and for 1 week following last&#xD;
                  dose of COV155&#xD;
&#xD;
          -  Male subjects must be sterile (biologically or surgically) or use reliable birth&#xD;
             control during the study until at least 1 week after the last dose of COV155&#xD;
&#xD;
          -  Classified as either Physical Status-1 (PS) or PS-2 by the American Society of&#xD;
             Anesthetists (ASA) Physical Status Classification System.&#xD;
&#xD;
          -  Willing to complete pain assessments and clinic visits.&#xD;
&#xD;
          -  Additional inclusion criterion for randomization into the Double-Blind Phase: Subjects&#xD;
             must experience postoperative pain intensity score ≥5 on a 0 to 10 Numerical Pain&#xD;
             Rating Score (NPRS) more than 1 hour, and less than 9 hours after discontinuing the&#xD;
             nerve block, and at least 30 minutes after the last ice pack has been removed (if&#xD;
             used).&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
          -  Uncontrolled medical condition, serious intercurrent illness, clinically significant&#xD;
             general health condition, or extenuating circumstance that may significantly decrease&#xD;
             study compliance or otherwise preclude study participation&#xD;
&#xD;
          -  Clinically significant abnormal ECG at Screening&#xD;
&#xD;
          -  Gastric bypass surgery or gastric band&#xD;
&#xD;
          -  Previous abdominal surgery within the past year or history of abdominal adhesions,&#xD;
             known or suspected paralytic ileus&#xD;
&#xD;
          -  History of any medical condition that would alter the absorption, distribution,&#xD;
             metabolism or excretion of COV155 including but not limited to severe chronic&#xD;
             diarrhea, chronic constipation, severe irritable bowel syndrome, or unexplained weight&#xD;
             loss&#xD;
&#xD;
          -  History of severe bronchial asthma, hypercarbia, hypoxia or sleep apnea&#xD;
&#xD;
          -  Certain lab abnormalities&#xD;
&#xD;
          -  Addison's disease, benign prostatic hyperplasia, or kidney disease&#xD;
&#xD;
          -  Donated blood or blood components within 3 months prior to Screening or during study&#xD;
&#xD;
          -  Known allergy/hypersensitivity to any opioid analgesics, anesthetics, acetaminophen,&#xD;
             non steroidal anti-inflammatory drugs (NSAIDs)&#xD;
&#xD;
          -  History of intolerance to short term opioid use&#xD;
&#xD;
          -  Unable to discontinue the use of prohibited medications or a history of substance or&#xD;
             alcohol abuse within 2 years prior to Screening or a positive quantitative urine drug&#xD;
             test at Screening&#xD;
&#xD;
          -  Positive for human immunodeficiency virus, hepatitis B or C&#xD;
&#xD;
          -  Dysphagia and/or cannot swallow study treatment whole&#xD;
&#xD;
          -  History of migraine or frequent headaches within the previous 2 years, seizures, or&#xD;
             are currently taking anticonvulsants&#xD;
&#xD;
          -  Previously received COV155 in a clinical study, or undergone a bunionectomy within the&#xD;
             last 3 months&#xD;
&#xD;
          -  Received any investigational drugs or devices within 4 weeks prior to Screening or&#xD;
             during study&#xD;
&#xD;
          -  Active malignancy or history of malignancy within 2 years prior to Screening, other&#xD;
             than completely eradicated cervical squamous cell carcinoma in situ or basal skin&#xD;
             cancer&#xD;
&#xD;
          -  Currently taking neuroleptics or stable doses of a benzodiazepine&#xD;
&#xD;
          -  Other criteria as specified in the protocol&#xD;
&#xD;
          -  Additional exclusion criterion for randomization into the Double-Blind Phase: Have&#xD;
             surgical complications that could compromise the safety of the subject or confound the&#xD;
             results of the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Anaheim Clinical Trials</name>
      <address>
        <city>Anaheim</city>
        <state>California</state>
        <zip>92801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lotus Clinical Research, LLC</name>
      <address>
        <city>Pasadena</city>
        <state>California</state>
        <zip>91105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chesapeake Research Group, LLC</name>
      <address>
        <city>Pasadena</city>
        <state>Maryland</state>
        <zip>21122</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Endeavor Clinical Trails, PA</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jean Brown Research, Inc.</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84124</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2016</verification_date>
  <study_first_submitted>December 4, 2012</study_first_submitted>
  <study_first_submitted_qc>December 5, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 6, 2012</study_first_posted>
  <disposition_first_submitted>October 10, 2014</disposition_first_submitted>
  <disposition_first_submitted_qc>October 10, 2014</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">October 20, 2014</disposition_first_posted>
  <last_update_submitted>October 18, 2016</last_update_submitted>
  <last_update_submitted_qc>October 18, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 19, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pain, Postoperative</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

